PATENT CLAIM ANALYSIS

Application Number: 15772302
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "211100"]

Abstract:
A method of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of a phosphatidylinositol 3-kinase inhibitor compound or a pharmaceutically acceptable salt thereof once-per-day either on a continuous daily schedule or an intermittent schedule at about zero to about three hours prior to sleep; a therapeutic regimen comprising administration of said compound or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.

Claim (Index 20):
A method according to  claim 1 , wherein the proliferative disease is a cancer selected from a cancer of the lung, bronchus, prostate, breast (including sporadic breast cancers and sufferers of Cowden disease), colon, rectum, colon carcinoma, colorectal adenoma, pancreas, gastrointestine, hepatocellular, stomach, gastric, ovary, squamous cell carcinoma, and head and neck.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 91.0
- Lexical Diversity: 1.49123
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15719636', '12208227', '12763991', '14661656', '13799076']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.736952961166653
- 35 USC 102 Novelty (BERT): 0.5745987615780419
- Combined Prediction Score: 0.720717541207792
- Mean Citation Score: 350.428222
- Max Citation Score: 458.44656
- Similarity Product: 383.5320499139786

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test